Clinical trials
Peritoneal Metastases From Colorectal Cancer clinical trials
Below are recruiting peritoneal metastases from colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 63 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07411599RecruitingPhase 1/Phase 2
CAR-NK cell therapy plus cetuximab for belly-spread colorectal cancer
This trial tests a new cell therapy (CAR-NK cells given directly into your belly and a vein) combined with a targeted drug (cetuximab) for colorectal cancer that has spread mainly to the lining of your belly. It aims to see if this treatment can shrink tumors and help people who have run out of standard chemotherapy options.
Houston, TexasAges 18 years+ - NCT07581912RecruitingPhase 2
Fulzerasib Plus Cetuximab for Advanced Colorectal Cancer With KRAS G12C
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
Hangzhou, ZhejiangAges 18–85 - NCT06959589Enrolling by invitationPhase 2
Combination therapy for KRAS G12C mutated colorectal cancer
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Hangzhou, ZhejiangAges 18–75 - NCT06563986RecruitingPhase 2
Combination therapy for advanced colorectal cancer in the liver
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
UtrechtAges 18 years+ - NCT06630624RecruitingPhase 1/Phase 2
IP-001 with ablation for colorectal liver metastases
This trial tests whether adding the drug IP-001 to tumor ablation (microwave or irreversible electroporation) helps control colorectal cancer that has spread to the liver. The goal is to find the best dose and see how the immune system responds.
Amsterdam, North HollandAges 18 years+ - NCT06654037RecruitingPhase 1
Testing abemaciclib plus 5-FU for advanced colorectal cancer
This trial is testing whether adding a targeted drug called abemaciclib to the standard chemotherapy 5-FU can help people with a specific type of advanced colorectal cancer (MSS) that has stopped responding to other treatments. The goal is to see if this combination is safe and effective.
Irvine, CaliforniaAges 18 years+ - NCT06825624RecruitingPhase 1
Testing HS-20093 combinations for advanced colorectal cancer
This trial tests a new drug combination (HS-20093) for people with advanced colorectal cancer that has spread or cannot be removed by surgery. It aims to see if the combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT06887218RecruitingPhase 2
Testing a new combination for advanced colorectal cancer
This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT07079631RecruitingPhase 1/Phase 2
Testing BNT314 with pumitamig and chemo for advanced colorectal cancer
This trial tests a new combination of drugs (BNT314 and pumitamig) plus chemotherapy for people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT07607873Recruiting
Transplant vs surgery after chemo for liver-only colorectal cancer
This trial compares liver transplant versus liver surgery for people whose colorectal cancer has spread only to the liver and cannot be removed initially. You would first receive chemotherapy to shrink the tumors, and if they become removable, you may be randomly assigned to have a liver transplant or standard liver surgery.
MilanAges 18 years+ - NCT05673148RecruitingPhase 3
Ablation treatment plus usual therapy for limited metastatic bowel cancer
This study tests whether adding “total ablation” (carefully destroying all visible small tumors using surgery, heat/cold treatment, and/or targeted radiation) to standard chemotherapy improves outcomes for people with limited spread of colorectal cancer. It may help by aiming to eliminate all known metastatic spots while you continue usual cancer treatment.
Kingman, ArizonaAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06607458RecruitingPhase 2
Liver-focused chemo for metastatic colorectal cancer
This trial tests giving high-dose melphalan directly into the liver's blood supply, followed by standard cancer therapy, for people whose colorectal cancer has spread mainly to the liver. The goal is to see if this approach is safer and works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT03659448RecruitingPhase 3
Test drug that helps map colon and rectal cancer during surgery
This Phase 3 study tests SGM-101, a drug used during surgery to help doctors better outline primary, recurrent, and spread (metastatic) colorectal cancer. It may improve how completely tumors are identified and removed during an operation.
Duarte, CaliforniaAges 18 years+ - NCT05803382RecruitingPhase 1
Adding a new drug to capecitabine for metastatic colorectal cancer
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
Irvine, CaliforniaAges 18 years+ - NCT04930432RecruitingPhase 1/Phase 2
MCLA-129 for advanced EGFR- and MET-positive lung and other cancers
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
BaodingAges 18 years+ - NCT07056374Recruiting
New bowel connection method for colon or rectal cancer surgery
This trial tests a new way of connecting the bowel after removing cancer or precancerous lesions in the sigmoid colon or upper rectum. It is for patients who are having planned, curative surgery and may help reduce complications.
AmsterdamAges 18 years+ - NCT07281768RecruitingPhase 2
Chemo and immunotherapy for locally advanced rectal cancer
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
Baltimore, MarylandAges 18 years+ - NCT07543744RecruitingPhase 1
Comparing RPH-030 to Vectibix for metastatic colorectal cancer
This trial tests whether a new drug called RPH-030 works similarly to an existing drug called Vectibix in treating advanced colorectal cancer that has spread. Both drugs will be given alongside chemotherapy (FOLFIRI) as a first-line treatment.
ArkhangelskAges 18 years+ - NCT05236972RecruitingPhase 3
PD-1 antibody after colon cancer surgery for dMMR stage III
This phase 3 trial studies a PD-1 antibody medicine given after surgery to help prevent stage III colon cancer from coming back. It is specifically for people whose tumor is mismatch repair–defective (dMMR) or MSI-H, which may make the cancer more responsive to immune-based treatment.
GuangzhouAges 18–75 - NCT05706779RecruitingPhase 2
Encorafenib plus cetuximab before surgery for BRAF-mutated colon cancer
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
ParisAges 18 years+ - NCT07257653RecruitingPhase 2
Cetuximab beta plus fruquintinib with or without immunotherapy for first-line advanced colorectal cancer
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
Hangzhou, ZhejiangAges 10–85 - NCT07544589RecruitingPhase 1
Testing DISP-10 for Advanced Gastrointestinal Cancers
This early-stage trial tests a new experimental therapy called DISP-10 in patients with advanced cancers of the stomach, esophagus, or colon that have spread. The goal is to see if this treatment can help shrink tumors and how safe it is.
Duarte, CaliforniaAges 18 years+ - NCT06061874Recruiting
New PET scan for spotting cancer spread in the abdomen
This trial tests a new type of PET scan (Ga68-FAPI-46) to better see if cancer from the colon, rectum, or ovary has spread to the lining of the belly. If you are already scheduled for surgery to remove these cancer spots, this scan may help your doctors plan a more complete operation.
BrusselsAges 18 years+
Hear when a new Peritoneal Metastases From Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for peritoneal metastases from colorectal cancer?
- Yes. Clin2 currently lists 63 recruiting peritoneal metastases from colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peritoneal metastases from colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peritoneal metastases from colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Liver Metastases From Colorectal Cancer
- Colorectal Cancer Liver Metastases (CRLM)
- Gastric Cancer Peritoneal Metastases
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Brain Metastases From Breast Cancer
- Metastatic Colorectal Cancer
- Colorectal Cancer (CRC)
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.